lopinavir has been researched along with Carcinoma, Anaplastic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allwood, JW; Goodacre, R; Hampson, IN; Hampson, L; Jarvis, RM; Kim, DH; Oliver, AW; Xu, Y | 1 |
| Hampson, IN; Hampson, L; Kitchener, HC | 1 |
2 other study(ies) available for lopinavir and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Combining metabolic fingerprinting and footprinting to understand the phenotypic response of HPV16 E6 expressing cervical carcinoma cells exposed to the HIV anti-viral drug lopinavir.
Topics: Anti-HIV Agents; Carcinoma; Cell Line, Tumor; Female; Humans; Lopinavir; Metabolomics; Oncogene Proteins, Viral; Phenotype; Principal Component Analysis; Pyrimidinones; Repressor Proteins; Spectroscopy, Fourier Transform Infrared; Uterine Cervical Neoplasms | 2010 |
Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro.
Topics: Animals; Carcinoma; Cell Line, Tumor; Female; HIV Protease Inhibitors; Humans; Lopinavir; Mice; NIH 3T3 Cells; Oncogene Proteins, Viral; Proteasome Endopeptidase Complex; Pyrimidinones; Repressor Proteins; Transfection; Tumor Suppressor Protein p53; Uterine Cervical Neoplasms | 2006 |